Curium Pharma and HIG Capital are among shortlisted bidders for Cardinal Health’s nuclear medicine unit, Bloomberg’s Dinesh Nair and Michelle F. Davis report, citing people familiar with the matter. Cardinal has invited the remaining suitors to submit final offers by the middle of next month, the authors note. A deal could value the unit at roughly $2B or higher, the authors say. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CAH:
- Cardinal Health price target raised to $88 from $77 at Deutsche Bank
- GeneDx appoints Devin Schaffer as general counsel
- Cardinal Health initiated with a Neutral at Citi
- Cardinal Health exploring possible sale of nuclear medicine unit, Bloomberg says
- Cardinal Health price target lowered to $77 from $82 at Deutsche Bank
